Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

被引:7
|
作者
Moon, Rebecca J. [1 ,2 ]
Reginster, Jean-Yves [3 ,4 ]
Al-Daghri, Nasser M. [5 ]
Thiyagarajan, Jotheeswaran A. [6 ]
Beaudart, Charlotte [3 ,4 ]
Bruyere, Olivier [3 ,4 ]
Burlet, Nansa [4 ]
Chandran, Manju [7 ]
da Silva, Mario Coelho [8 ]
Conaghan, Philip G. [9 ,10 ]
Dere, Willard H. [11 ]
Diez-Perez, Adolfo [12 ,13 ]
Hadji, Peyman [14 ,15 ]
Halbout, Philippe [16 ]
Hiligsmann, Mickael [17 ]
Kanis, John A. [18 ,19 ]
McCloskey, Eugene V. [20 ,21 ]
Ormarsdottir, Sif [22 ]
Prieto-Alhambra, Daniel [23 ]
Radermecker, Regis P. [24 ]
Rizzoli, Rene [25 ,26 ]
Al-Saleh, Yousef [27 ,28 ,29 ]
Silverman, Stuart L. [30 ]
Simon, Lee S. [31 ]
Thomasius, Friederike [14 ]
van Staa, Tjeerd [32 ]
Laslop, Andrea [33 ]
Cooper, Cyrus [1 ,34 ,35 ,36 ]
Harvey, Nicholas C. [1 ,34 ,35 ]
机构
[1] Univ Southampton, MRC Lifecourse Epidemiol Ctr, Southampton SO16 6YD, England
[2] Univ Hosp Southampton NHS Fdn Trust, Paediat Endocrinol, Southampton, England
[3] WHO, Collaborating Ctr Epidemiol Musculoskeletal Hlth, Liege, Belgium
[4] Univ Liege, Div Epidemiol Publ Hlth & Hlth Econ, Liege, Belgium
[5] King Saud Univ, Dept Biochem, Coll Sci, Riyadh, Saudi Arabia
[6] World Hlth Org, Ageing & Hlth Unit, Geneva, Switzerland
[7] Singapore Gen Hosp, Dept Endocrinol, Osteoporosis & Bone Metab Unit, Singapore, Singapore
[8] Lab Clin & Therapeut Pharmacol, Lisbon, Portugal
[9] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
[10] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, England
[11] Univ Utah, Sch Med, Dept Internal Med, Utah Ctr Clin & Translat Sci, Salt Lake City, UT USA
[12] Autonomous Univ Barcelona, Dept Internal Med, Hosp Mar, IMIM, Barcelona, Spain
[13] CIBERFES, Inst Carlos III, Barcelona, Spain
[14] Frankfurt Ctr Bone Hlth, Frankfurt, Germany
[15] Philipps Univ Marburg, Hesse, Germany
[16] Int Osteoporosis Fdn, Nyon, Switzerland
[17] Maastricht Univ, Dept Hlth Serv Res, CAPHRI Care & Publ Hlth Res Inst, Maastricht, Netherlands
[18] Australian Catholic Univ, Mary McKillop Inst Hlth Res, Melbourne, Australia
[19] Univ Sheffield, Ctr Metab Bone Dis, Sheffield, England
[20] Univ Sheffield, MRC Versus Arthrit Ctr Integrated Res Musculoskel, Sheffield, England
[21] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Dept Oncol & Metab, Sheffield, England
[22] Icelandic Med Agcy, Reykjavik, Iceland
[23] Univ Oxford, Pharmaco & Device Epidemiol, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[24] CHU Liege, Dept Clin Pharmacol Diabet Nutr & Metab Disorders, Liege, Belgium
[25] Geneva Univ Hosp, Geneva, Switzerland
[26] Fac Med, Geneva, Switzerland
[27] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Med, Riyadh, Saudi Arabia
[28] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia
[29] Minist Natl Guard Hlth Affairs, Dept Med, King Abdulaziz Med City Riyadh, Riyadh, Saudi Arabia
[30] Cedars Sinai Med Ctr, Los Angeles, CA USA
[31] SDG LLC, Cambridge, MA USA
[32] Univ Manchester, Ctr Hlth Informat, Manchester, England
[33] Austrian Med & Med Devices Agcy, Sci Off, Vienna, Austria
[34] Univ Southampton, NIHR Southampton Biomed Res Ctr, Southampton, England
[35] Univ Hosp Southampton NHS Fdn Trust, Southampton, England
[36] Univ Oxford, Natl Inst Hlth Res NIHR, Musculoskeletal Biomed Res Ctr, Oxford, England
关键词
Drug effectiveness; Fracture; Osteoporosis; Real-world evidence; Epidemiology; Registry; MEDICATION ADHERENCE; PATIENT REGISTRY; BONE-DENSITY; FRACTURES; RISK; IDENTIFICATION; EPIDEMIOLOGY; ALENDRONATE; VALIDATION; THERAPIES;
D O I
10.1007/s00198-023-06827-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This narrative review summarises the recommendations of a Working Group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) for the conduct and reporting of real-world evidence studies with a focus on osteoporosis research. Purpose Vast amounts of data are routinely generated at every healthcare contact and activity, and there is increasing recognition that these real-world data can be analysed to generate scientific evidence. Real-world evidence (RWE) is increasingly used to delineate the natural history of disease, assess real-life drug effectiveness, understand adverse events and in health economic analysis. The aim of this work was to understand the benefits and limitations of this type of data and outline approaches to ensure that transparent and high-quality evidence is generated. Methods A ESCEO Working Group was convened in December 2022 to discuss the applicability of RWE to osteoporosis research and approaches to best practice. Results This narrative review summarises the agreed recommendations for the conduct and reporting of RWE studies with a focus on osteoporosis research. Conclusions It is imperative that research using real-world data is conducted to the highest standards with close attention to limitations and biases of these data, and with transparency at all stages of study design, data acquisition and curation, analysis and reporting to increase the trustworthiness of RWE study findings.
引用
收藏
页码:1283 / 1299
页数:17
相关论文
共 25 条
  • [21] Benefits and safety of dietary protein for bone health—an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation
    R. Rizzoli
    E. Biver
    J.-P. Bonjour
    V. Coxam
    D. Goltzman
    J. A. Kanis
    J. Lappe
    L. Rejnmark
    S. Sahni
    C. Weaver
    H. Weiler
    J.-Y. Reginster
    Osteoporosis International, 2018, 29 : 1933 - 1948
  • [22] Benefits and safety of dietary protein for bone health-an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation
    Rizzoli, R.
    Biver, E.
    Bonjour, J. -P.
    Coxam, V.
    Goltzman, D.
    Kanis, J. A.
    Lappe, J.
    Rejnmark, L.
    Sahni, S.
    Weaver, C.
    Weiler, H.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (09) : 1933 - 1948
  • [23] Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group
    Morland, Kellie
    Gerges, Christian
    Elwing, Jean
    Visovatti, Scott H.
    Weatherald, Jason
    Gillmeyer, Kari R.
    Sahay, Sandeep
    Mathai, Stephen C.
    Boucly, Athenais
    Williams, Paul G.
    Harikrishnan, Sivadasanpillai
    Minty, Evan P.
    Hobohm, Lukas
    Jose, Arun
    Badagliacca, Roberto
    Lau, Edmund M. T.
    Jing, Zhi-Cheng
    Vanderpool, Rebecca R.
    Fauvel, Charles
    Leonidas Alves, Jose, Jr.
    Strange, Geoff
    Pulido, Tomas
    Qian, Junyan
    Li, Mengtao
    Mercurio, Valentina
    Zelt, Jason G. E.
    Moles, Victor M.
    Cirulis, Meghan M.
    Nikkho, Sylvia M.
    Benza, Raymond L.
    Elliott, C. Gregory
    PULMONARY CIRCULATION, 2023, 13 (04)
  • [24] Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database
    Khalid, Sara
    Calderon-Larranaga, Sara
    Hawley, Samuel
    Ali, M. Sanni
    Judge, Andrew
    Arden, Nigel
    van Staa, Tjeerd
    Cooper, Cyrus
    Javaid, Muhammad Kassim
    Prieto-Alhambra, Daniel
    CLINICAL EPIDEMIOLOGY, 2018, 10 : 1417 - 1431
  • [25] Case definitions for acute coronary heart disease in epidemiology and clinical research studies - A statement from the AHA council on epidemiology and prevention; AHA Statistics Committee; World Heart Federation Council on epidemiology and prevention; the European Society of Cardiology working group on epidemiology and prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute
    Luepker, RV
    Apple, FS
    Christenson, RH
    Crow, RS
    Fortmann, SP
    Goff, D
    Goldberg, RJ
    Hand, MM
    Jaffe, AS
    Julian, DG
    Levy, D
    Manolio, T
    Mendis, S
    Mensah, G
    Pajak, A
    Prineas, RJ
    Reddy, S
    Roger, VL
    Rosamond, WD
    Shahar, E
    Sharrett, AR
    Sorlie, P
    Tunstall-Pedoe, H
    CIRCULATION, 2003, 108 (20) : 2543 - 2549